Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Developer of a portable, point-of-care hemodynamic measurement system that uses proprietary sensor tech and machine learning to guide care.
Vivasc Therapeutics is a drug development company that specializes in proprietary cardiac targeting peptide platform technology.
Vivita Technologies develops biomaterials for regenerative medicine, intending to alleviate the scarcity of donor organs and tissues.
Ontogen Medtech is a medical device development firm.
Biotricity is a medical technology company committed to improving healthcare by developing solutions that aid in chronic disease.
I CORDIS is a healthcare organization that offers services for treating heart failure.
Blue Marble Health is telehealth and remote therapeutic monitoring platform for aging and chronic disease management.
Lung and Blood Institute has invested in 55 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Lung and Blood Institute's top investment sectors include Health Care, Medical Device, Medical, Biotechnology, Artificial Intelligence (AI). The firm invests across 17 different industry categories.
Among tracked funding rounds, Sensydia received $3.0M in a Grant round. Lung and Blood Institute's total known invested capital is $198.9M.
Lung and Blood Institute's average investment size is $4.6M across its portfolio of 55 companies.
Recent Lung and Blood Institute portfolio additions include Sensydia, Vivasc Therapeutics, Vivita Technologies, Ontogen Medtech, Biotricity. These companies were founded in 2020 or later.